Sarepta Therapeutics Stock
€15.66
Your prediction
Sarepta Therapeutics Stock
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
Cons
Performance of Sarepta Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | 1.520% | 3.178% | -53.244% | -89.254% | -86.632% | -78.760% | -89.534% |
| Exact Sciences | -1.750% | 2.549% | -6.912% | 13.626% | -16.045% | 15.758% | -40.854% |
| Regeneron Pharmaceuticals Inc. | -0.410% | 3.897% | 8.236% | -52.274% | -31.416% | -18.742% | -16.218% |
| Incyte Corp. | 0.620% | -0.345% | 1.227% | 5.133% | -12.112% | -22.449% | -39.046% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Sarepta Therapeutics, traded under the symbol AVII, reflect a complex picture shaped by its positioning in the Biotechnology and Medical Research sector. The company has been heavily investing in research and development, which is crucial in this industry. However, the resulting financial statements indicate significant losses, raising queries about its future performance and viability. While the potential for groundbreaking advancements in treatment options exists, investors must weigh the current financial challenges against future possibilities carefully.
Market Capitalization: With a market capitalization of approximately $12.9 billion, Sarepta has a robust presence in the biotech sector. This positioning facilitates investment opportunities and potential market confidence, reflecting the belief in its future innovations.
Revenue Growth: Revenues for Sarepta totaled about $1.4 billion in the most recent twelve months (TTM). This suggests that the company has viable product lines, delivering growth opportunities despite the ongoing losses.
Comments
News
2 Beaten-Down Stocks to Avoid
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this